Year: 2026

Vancouver, British Columbia, April 02, 2026 (GLOBE NEWSWIRE) — NevGold Corp. (“NevGold” or the “Company”) (TSXV:NAU) (OTCQX:NAUFF) (Frankfurt:5E50) is pleased to announce further metallurgical testwork results on the residual tailings material from the positive Phase II antimony (“Antimony”, “Sb”) testwork included in the November 5, 2025 News Release. The residual tailings material from the antimony leaching process had remaining gold mineralization, and went through a second sequential stage of leaching testwork focused on gold. The positive sequential antimony and gold leaching results highlight the exceptional geo-metallurgical characteristics of the oxide antimony-gold Limousine Butte Project (the “Project”, “Limo Butte”) in Nevada, one of the world’s prolific mining jurisdictions. As the Company has stated in previous News...

VANCOUVER, British Columbia, April 02, 2026 (GLOBE NEWSWIRE) — Yukon Metals Corp. (CSE: YMC, FSE: E770, OTCQB: YMMCF) (“Yukon Metals” or the “Company”) is pleased to report results from a successful 2025 diamond drilling program at the Star River property (“Star River” or the “Property”) located adjacent to the past-producing Ketza mine in the southern Yukon, motivating the acquisition of additional, highly prospective, Stump claims along the same structural corridor. The 2025 drill campaign focused on testing the down-dip and along-strike extensions of gold and silver-bearing veins exposed at surface within the F2, F3 and Saddle zones. Holes successfully correlated geology with geophysical surveys, including electromagnetics, gravimetry and drone magnetics defining a 1-kilometre-long structural mineralized corridor containing multiple...

NEW YORK, April 02, 2026 (GLOBE NEWSWIRE) — MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat immune-mediated diseases and cancer, today announced that an abstract featuring its investigational iNKT cell therapy, agenT-797, has been accepted for presentation at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, taking place May 11-15, 2026, in Boston, MA. Presentation Details:Abstract Title: AgenT-797 Allogeneic iNKT Cell Therapy Demonstrates Adaptive Immune Modulation in Cancer and ARDS Presenter: Terese C. Hammond, MD; Program Director of Pulmonary and Critical Care, Kaweah Health Medical Center; Head of Inflammatory and Pulmonary Diseases, MiNK TherapeuticsAdditional...

VANCOUVER, British Columbia, April 02, 2026 (GLOBE NEWSWIRE) — Domestic Metals Corp. (the “Company” or “Domestic Metals”) – (TSXV: DMCU; OTCQB: DMCUF; FSE: 03E0) is pleased to report that a recently completed induced polarization (“IP”) geophysical survey at its Smart Creek copper-gold-silver Project in Montana (Figure 1) identified chargeability features that support the project’s target potential. The newly enhanced targets include extensive porphyry copper style zones in addition to carbonate replacement (“CRD”)/skarn copper-gold silver mineralization. The IP chargeability features of interest are widespread, coincident with previously established alteration footprints and high-grade sampling carried out by the Company (see news release dated January 8, 2026). The IP targets are interpreted to represent previously untested...

Fast Track Designation highlights potential of CTIM-76 to address unmet need for patients with PROC CTIM-76 Phase 1a trial ongoing, with interim data expected in June 2026 PHILADELPHIA, April 02, 2026 (GLOBE NEWSWIRE) — Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track Designation to CTIM-76, a CLDN6 x CD3 T cell engaging bispecific antibody, for the treatment of platinum-resistant ovarian cancer (“PROC”) in patients that have received all standard of care therapies. Context is currently evaluating CTIM-76 in a Phase 1 clinical trial designed to evaluate the safety and efficacy of CTIM-76 in subjects with...

HOUSTON, April 02, 2026 (GLOBE NEWSWIRE) — CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), today announces a new payer coverage agreement with Highmark, effective April 1, 2026, providing reimbursement for its CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay for patients with metastatic central nervous system cancers. Highmark joins a growing list of national and regional payers, including United Healthcare and Humana, that provide coverage for CNSide. The addition of Highmark expands CNSide’s total covered lives from approximately 67 million to 75 million, representing continued progress toward the Company’s 2026 objective of 150 million covered lives, while expanding patient access across the U.S. The agreement is expected to further accelerate...

Campaign to test extension of pegmatite system and evaluatepotential for niobium and rare earths Vancouver, British Columbia, April 02, 2026 (GLOBE NEWSWIRE) — Drills are turning for the first time at North American Niobium and Critical Minerals Corp.’s (CSE: NIOB) (FSE: KS82.F) (OTCQB: NIOMF) (North American Niobium or the Company) Seigneurie Project. “The team has wasted no time. We announced receipt of the key authorization last week, and the drill is already running this week. This first phase is designed to test the extension of the pegmatite system and evaluate its potential to host niobium and rare earth mineralization,” said Murray Nye, North American Niobium’s Chief Executive Officer. “The results will help guide the next stage of exploration at Seigneurie.” HighlightsDiamond drilling has commenced at the 100%-owned Seigneurie...